Новости за 10.08.2018

Turkey’s crisis is by no means a black swan event as trouble had been brewing in the country for several months. Still, fears of a spillover effect from the currency crisis in the world’s 17th largest economy are playing havoc with the global financial markets Friday as panicked investors run for cover.

Oil prices settle higher Friday as a forecast for rising global crude demand, and supply boosts from Russia, offset lingering concerns about trade tensions cutting global consumption of energy products.

U.S. government bonds rally Friday, driving yields to their sharpest yield decline since late May as turmoil in Europe, sparked by questions about a knock-on effect from economic distress in Turkey, rattles investors’ sentiment and sent them fleeing to the perceived safety of sovereign paper.

The largest exchange-traded fund to track Turkey's equity market plummeted on Friday after the European Central Bank raised questions about a possible contagion from Turkey's embattled currency, according to a report form the Financial Times. President Recep Tayyip Erdogan won reelection in a snap vote in June and his growing power in Ankara has unsettled investors because he threatens the independence of the country's central bank. The iShares MSCI Turkey ETF closed down by about 14.5%, marking its worst day since Oct. Читать дальше...

Confirmation hearings for President Donald Trump's Supreme Court nominee Brett Kavanaugh are scheduled to begin on Sept. 4, Senate Judiciary Committee Chairman Charles Grassley said Friday. Grassley said he expects hearings to last for three or four days. Earlier Friday, Senate Majority Leader Mitch McConnell said in a radio interview he hopes to have Trump's nominee confirmed "before the first Monday in October."

VF Corp. is weighing strategic alternatives for its jeans business, including a sale or spin off.

U.S. stocks closed solidly lower on Friday, joining a global equity market selloff, as the mounting currency crisis in Turkey raised the alarm for possible contagion into other markets. Friday's losses turned what would have been weekly gains into losses. Implied volatility as measured by the Cboe Volatiliy Index jumped 19% to 13.41, its highest in a week. The S&P 500 fell 20.30 points, or 0.7%, to 2,833.28 and posted a 0.3% weekly loss, breaking a five-week advance. The Dow Jones Industrial Average dropped 196.16 points... Читать дальше...

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news.

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news.

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news.

Stocks made a small comeback near the close but still finished solidly lower

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news.

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news.

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news.

Alnylam Pharmaceuticals Inc.'s rare disease drug Onpattro has been approved by the Food and Drug Administration, marking the first approval of a therapy that employs the RNA interference (RNAi) gene-silencing technique. Onpattro, also called patisiran, is also the first FDA-approved drug for the rare and progressive disease hereditary ATTR amyloidosis with polyneuropathy, or malfunction of bodily nerves. It was shown in clinical trials to improve polyneuropathy and other symptoms. The drug will have an average annual list price of $450,000... Читать дальше...

Gold futures on Friday finish the session with a loss for the day and the week, as a sharp jump in the dollar overshadowed growing worries that an escalating currency crisis in Turkey would spill over in to parts of the globe.

The duo can answer questions about debt and even help with LGBT-specific financial questions

Social Security’s ‘early claimers’ often regret their decision

This man wants to know whether he has any legal recourse after supporting his girlfriend for three years.

Removing money from a ‘taxable environment’

Donald Trump is a “racist” who regularly used the “N-word” on the set of “The Apprentice,” claims Omarosa Manigault Newman, who starred on the show and then followed the president to the White House.

Don’t spend your free time spending.

Shares of Mesa Air Group Inc. fell in their debut, and were trading 4.2% below the initial public offering price of $12 in afternoon trade Friday. The regional air carrier's IPO priced late Thursday below the expected range of $14 to $16. The first trade was at $12 at 10:50 a.m. Eastern, and it has traded in a range of $11.50 to $12 since then. The air carrier has gone public at a time that the NYSE Arca Airline Index has lost 2.0% over the past three months and the S&P 500 has gained 3.8%.

Alnylam Pharmaceuticals Inc. shares were halted in Friday trade before news that its rare disease drug Onpattro was approved by the Food and Drug Administration, marking the first approval of a therapy that employs the RNA interference (RNAi) gene-silencing technique. Onpattro, also called patisiran, is intended for the rare and progressive disease hereditary ATTR amyloidosis with polyneuropathy, or malfunction of bodily nerves, and was shown in clinical trials to improve polyneuropathy and other symptoms. Читать дальше...

Retirement news and analysis.